LINC 24 - In this short interview, Dr Marianne Brodmann (Medical University of Graz, AT) discusses the angiographic and clinical outcomes of the R3 Vascular MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in patients receiving treatment for peripheral arterial disease (PAD).

The RESOLV-I trial (NCT04912323) is an early-feasability study that enrolled 30 patients with below-the-knee disease to recieve the MAGNITUDE® Bioresorbable Scaffold.

Interview Questions:

1. What is the reasoning for this study?
2. Could you tell us about the MAGNITUDE bioresorbable scaffold?
3. What was the patient population and study design?
4. What are the key findings?
5. What further research is needed, and what are the next steps?

Recorded remotely from Graz, 2024.